

# Hematological Malignancies Disease Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/HF272CB0F3A6EN.html>

Date: March 2022

Pages: 118

Price: US\$ 3,250.00 (Single User License)

ID: HF272CB0F3A6EN

## Abstracts

This report contains market size and forecasts of RF Power Amplifier for Cellular Terminal in global, including the following market information:

Global RF Power Amplifier for Cellular Terminal Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global RF Power Amplifier for Cellular Terminal Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five RF Power Amplifier for Cellular Terminal companies in 2021 (%)

The global RF Power Amplifier for Cellular Terminal market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

GSM Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of RF Power Amplifier for Cellular Terminal include Skyworks, Broadcom, Qorvo, Microchip Technology, Murata, Qualcomm, Texas Instruments, Analog Devices and Maxim Integrated and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the RF Power Amplifier for

Cellular Terminal manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global RF Power Amplifier for Cellular Terminal Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global RF Power Amplifier for Cellular Terminal Market Segment Percentages, by Type, 2021 (%)

GSM

CDMA

3G/4G

M/M PAM

Global RF Power Amplifier for Cellular Terminal Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global RF Power Amplifier for Cellular Terminal Market Segment Percentages, by Application, 2021 (%)

Traditional Handset

Smart Phone

Dongle for WWAN

Cellular-Compatible Notebook PC

Cellular-Compatible E-book/Tablet

Others

Global RF Power Amplifier for Cellular Terminal Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global RF Power Amplifier for Cellular Terminal Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies RF Power Amplifier for Cellular Terminal revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies RF Power Amplifier for Cellular Terminal revenues share in global market, 2021 (%)

Key companies RF Power Amplifier for Cellular Terminal sales in global market, 2017-2022 (Estimated), (K Units)

Key companies RF Power Amplifier for Cellular Terminal sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Skyworks

Broadcom

Qorvo

Microchip Technology

Murata

Qualcomm

Texas Instruments

Analog Devices

Maxim Integrated

Renesas Electronics Corporation

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Hematological Malignancies Disease Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Hematological Malignancies Disease Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL HEMATOLOGICAL MALIGNANCIES DISEASE OVERALL MARKET SIZE**

- 2.1 Global Hematological Malignancies Disease Market Size: 2021 VS 2028
- 2.2 Global Hematological Malignancies Disease Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Hematological Malignancies Disease Players in Global Market
- 3.2 Top Global Hematological Malignancies Disease Companies Ranked by Revenue
- 3.3 Global Hematological Malignancies Disease Revenue by Companies
- 3.4 Top 3 and Top 5 Hematological Malignancies Disease Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hematological Malignancies Disease Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancies Disease Players in Global Market
  - 3.6.1 List of Global Tier 1 Hematological Malignancies Disease Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancies Disease Companies

## **4 MARKET SIGHTS BY PRODUCT**

### 4.1 Overview

4.1.1 by Type - Global Hematological Malignancies Disease Market Size Markets, 2021 & 2028

4.1.2 Chemotherapy

4.1.3 Immunotherapy

4.1.4 Targeted Therapy

4.1.5 Radiotherapy

4.1.6 Stem Cell Transplantation

4.1.7 Others

4.2 By Type - Global Hematological Malignancies Disease Revenue & Forecasts

4.2.1 By Type - Global Hematological Malignancies Disease Revenue, 2017-2022

4.2.2 By Type - Global Hematological Malignancies Disease Revenue, 2023-2028

4.2.3 By Type - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

### 5.1 Overview

5.1.1 By Application - Global Hematological Malignancies Disease Market Size, 2021 & 2028

5.1.2 Leukemia

5.1.3 Lymphoma

5.1.4 Myeloma

5.1.5 Others

5.2 By Application - Global Hematological Malignancies Disease Revenue & Forecasts

5.2.1 By Application - Global Hematological Malignancies Disease Revenue, 2017-2022

5.2.2 By Application - Global Hematological Malignancies Disease Revenue, 2023-2028

5.2.3 By Application - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028

## **6 SIGHTS BY REGION**

6.1 By Region - Global Hematological Malignancies Disease Market Size, 2021 & 2028

6.2 By Region - Global Hematological Malignancies Disease Revenue & Forecasts

6.2.1 By Region - Global Hematological Malignancies Disease Revenue, 2017-2022

6.2.2 By Region - Global Hematological Malignancies Disease Revenue, 2023-2028

6.2.3 By Region - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hematological Malignancies Disease Revenue, 2017-2028

6.3.2 US Hematological Malignancies Disease Market Size, 2017-2028

6.3.3 Canada Hematological Malignancies Disease Market Size, 2017-2028

6.3.4 Mexico Hematological Malignancies Disease Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hematological Malignancies Disease Revenue, 2017-2028

6.4.2 Germany Hematological Malignancies Disease Market Size, 2017-2028

6.4.3 France Hematological Malignancies Disease Market Size, 2017-2028

6.4.4 U.K. Hematological Malignancies Disease Market Size, 2017-2028

6.4.5 Italy Hematological Malignancies Disease Market Size, 2017-2028

6.4.6 Russia Hematological Malignancies Disease Market Size, 2017-2028

6.4.7 Nordic Countries Hematological Malignancies Disease Market Size, 2017-2028

6.4.8 Benelux Hematological Malignancies Disease Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hematological Malignancies Disease Revenue, 2017-2028

6.5.2 China Hematological Malignancies Disease Market Size, 2017-2028

6.5.3 Japan Hematological Malignancies Disease Market Size, 2017-2028

6.5.4 South Korea Hematological Malignancies Disease Market Size, 2017-2028

6.5.5 Southeast Asia Hematological Malignancies Disease Market Size, 2017-2028

6.5.6 India Hematological Malignancies Disease Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hematological Malignancies Disease Revenue, 2017-2028

6.6.2 Brazil Hematological Malignancies Disease Market Size, 2017-2028

6.6.3 Argentina Hematological Malignancies Disease Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hematological Malignancies Disease Revenue, 2017-2028

6.7.2 Turkey Hematological Malignancies Disease Market Size, 2017-2028

6.7.3 Israel Hematological Malignancies Disease Market Size, 2017-2028

6.7.4 Saudi Arabia Hematological Malignancies Disease Market Size, 2017-2028

6.7.5 UAE Hematological Malignancies Disease Market Size, 2017-2028

## **7 PLAYERS PROFILES**



## 7.1 Affymetrix

7.1.1 Affymetrix Corporate Summary

7.1.2 Affymetrix Business Overview

7.1.3 Affymetrix Hematological Malignancies Disease Major Product Offerings

7.1.4 Affymetrix Hematological Malignancies Disease Revenue in Global Market (2017-2022)

7.1.5 Affymetrix Key News

## 7.2 SkylineDx

7.2.1 SkylineDx Corporate Summary

7.2.2 SkylineDx Business Overview

7.2.3 SkylineDx Hematological Malignancies Disease Major Product Offerings

7.2.4 SkylineDx Hematological Malignancies Disease Revenue in Global Market (2017-2022)

7.2.5 SkylineDx Key News

## 7.3 AgenaBio

7.3.1 AgenaBio Corporate Summary

7.3.2 AgenaBio Business Overview

7.3.3 AgenaBio Hematological Malignancies Disease Major Product Offerings

7.3.4 AgenaBio Hematological Malignancies Disease Revenue in Global Market (2017-2022)

7.3.5 AgenaBio Key News

## 7.4 Signal Genetics

7.4.1 Signal Genetics Corporate Summary

7.4.2 Signal Genetics Business Overview

7.4.3 Signal Genetics Hematological Malignancies Disease Major Product Offerings

7.4.4 Signal Genetics Hematological Malignancies Disease Revenue in Global Market (2017-2022)

7.4.5 Signal Genetics Key News

## 7.5 Pfizer

7.5.1 Pfizer Corporate Summary

7.5.2 Pfizer Business Overview

7.5.3 Pfizer Hematological Malignancies Disease Major Product Offerings

7.5.4 Pfizer Hematological Malignancies Disease Revenue in Global Market (2017-2022)

7.5.5 Pfizer Key News

## 7.6 Roche

7.6.1 Roche Corporate Summary

7.6.2 Roche Business Overview

- 7.6.3 Roche Hematological Malignancies Disease Major Product Offerings
- 7.6.4 Roche Hematological Malignancies Disease Revenue in Global Market (2017-2022)
- 7.6.5 Roche Key News
- 7.7 Sanofi-Aventis
  - 7.7.1 Sanofi-Aventis Corporate Summary
  - 7.7.2 Sanofi-Aventis Business Overview
  - 7.7.3 Sanofi-Aventis Hematological Malignancies Disease Major Product Offerings
  - 7.7.4 Sanofi-Aventis Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.7.5 Sanofi-Aventis Key News
- 7.8 Cancer Genetics Inc
  - 7.8.1 Cancer Genetics Inc Corporate Summary
  - 7.8.2 Cancer Genetics Inc Business Overview
  - 7.8.3 Cancer Genetics Inc Hematological Malignancies Disease Major Product Offerings
  - 7.8.4 Cancer Genetics Inc Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.8.5 Cancer Genetics Inc Key News
- 7.9 Illumina
  - 7.9.1 Illumina Corporate Summary
  - 7.9.2 Illumina Business Overview
  - 7.9.3 Illumina Hematological Malignancies Disease Major Product Offerings
  - 7.9.4 Illumina Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.9.5 Illumina Key News
- 7.10 NeoGenomics
  - 7.10.1 NeoGenomics Corporate Summary
  - 7.10.2 NeoGenomics Business Overview
  - 7.10.3 NeoGenomics Hematological Malignancies Disease Major Product Offerings
  - 7.10.4 NeoGenomics Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.10.5 NeoGenomics Key News
- 7.11 Exiqon
  - 7.11.1 Exiqon Corporate Summary
  - 7.11.2 Exiqon Business Overview
  - 7.11.3 Exiqon Hematological Malignancies Disease Major Product Offerings
  - 7.11.4 Exiqon Hematological Malignancies Disease Revenue in Global Market (2017-2022)

- 7.11.5 Exiqon Key News
- 7.12 Regulus Therapeutics
  - 7.12.1 Regulus Therapeutics Corporate Summary
  - 7.12.2 Regulus Therapeutics Business Overview
  - 7.12.3 Regulus Therapeutics Hematological Malignancies Disease Major Product Offerings
  - 7.12.4 Regulus Therapeutics Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.12.5 Regulus Therapeutics Key News
- 7.13 Rosetta Genomics
  - 7.13.1 Rosetta Genomics Corporate Summary
  - 7.13.2 Rosetta Genomics Business Overview
  - 7.13.3 Rosetta Genomics Hematological Malignancies Disease Major Product Offerings
  - 7.13.4 Rosetta Genomics Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.13.5 Rosetta Genomics Key News
- 7.14 Sequentia
  - 7.14.1 Sequentia Corporate Summary
  - 7.14.2 Sequentia Business Overview
  - 7.14.3 Sequentia Hematological Malignancies Disease Major Product Offerings
  - 7.14.4 Sequentia Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.14.5 Sequentia Key News
- 7.15 Takeda Pharma
  - 7.15.1 Takeda Pharma Corporate Summary
  - 7.15.2 Takeda Pharma Business Overview
  - 7.15.3 Takeda Pharma Hematological Malignancies Disease Major Product Offerings
  - 7.15.4 Takeda Pharma Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.15.5 Takeda Pharma Key News
- 7.16 Celgene
  - 7.16.1 Celgene Corporate Summary
  - 7.16.2 Celgene Business Overview
  - 7.16.3 Celgene Hematological Malignancies Disease Major Product Offerings
  - 7.16.4 Celgene Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.16.5 Celgene Key News
- 7.17 Amgen

- 7.17.1 Amgen Corporate Summary
- 7.17.2 Amgen Business Overview
- 7.17.3 Amgen Hematological Malignancies Disease Major Product Offerings
- 7.17.4 Amgen Hematological Malignancies Disease Revenue in Global Market (2017-2022)
- 7.17.5 Amgen Key News
- 7.18 Ono Pharma
  - 7.18.1 Ono Pharma Corporate Summary
  - 7.18.2 Ono Pharma Business Overview
  - 7.18.3 Ono Pharma Hematological Malignancies Disease Major Product Offerings
  - 7.18.4 Ono Pharma Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.18.5 Ono Pharma Key News
- 7.19 Abbott
  - 7.19.1 Abbott Corporate Summary
  - 7.19.2 Abbott Business Overview
  - 7.19.3 Abbott Hematological Malignancies Disease Major Product Offerings
  - 7.19.4 Abbott Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.19.5 Abbott Key News
- 7.20 BMS
  - 7.20.1 BMS Corporate Summary
  - 7.20.2 BMS Business Overview
  - 7.20.3 BMS Hematological Malignancies Disease Major Product Offerings
  - 7.20.4 BMS Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.20.5 BMS Key News
- 7.21 Mundipharma
  - 7.21.1 Mundipharma Corporate Summary
  - 7.21.2 Mundipharma Business Overview
  - 7.21.3 Mundipharma Hematological Malignancies Disease Major Product Offerings
  - 7.21.4 Mundipharma Hematological Malignancies Disease Revenue in Global Market (2017-2022)
  - 7.21.5 Mundipharma Key News
- 7.22 Novartis
  - 7.22.1 Novartis Corporate Summary
  - 7.22.2 Novartis Business Overview
  - 7.22.3 Novartis Hematological Malignancies Disease Major Product Offerings
  - 7.22.4 Novartis Hematological Malignancies Disease Revenue in Global Market

(2017-2022)

7.22.5 Novartis Key News

7.23 MorphoSys

7.23.1 MorphoSys Corporate Summary

7.23.2 MorphoSys Business Overview

7.23.3 MorphoSys Hematological Malignancies Disease Major Product Offerings

7.23.4 MorphoSys Hematological Malignancies Disease Revenue in Global Market

(2017-2022)

7.23.5 MorphoSys Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Hematological Malignancies Disease Market Opportunities & Trends in Global Market
- Table 2. Hematological Malignancies Disease Market Drivers in Global Market
- Table 3. Hematological Malignancies Disease Market Restraints in Global Market
- Table 4. Key Players of Hematological Malignancies Disease in Global Market
- Table 5. Top Hematological Malignancies Disease Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Hematological Malignancies Disease Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Hematological Malignancies Disease Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Hematological Malignancies Disease Product Type
- Table 9. List of Global Tier 1 Hematological Malignancies Disease Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Hematological Malignancies Disease Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Hematological Malignancies Disease Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Hematological Malignancies Disease Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Hematological Malignancies Disease Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Hematological Malignancies Disease Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Hematological Malignancies Disease Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Hematological Malignancies Disease Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Hematological Malignancies Disease Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Hematological Malignancies Disease Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Hematological Malignancies Disease Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Hematological Malignancies Disease Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Hematological Malignancies Disease Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hematological Malignancies Disease Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hematological Malignancies Disease Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hematological Malignancies Disease Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hematological Malignancies Disease Revenue, (US\$, Mn), 2023-2028

Table 30. Affymetrix Corporate Summary

Table 31. Affymetrix Hematological Malignancies Disease Product Offerings

Table 32. Affymetrix Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 33. SkylineDx Corporate Summary

Table 34. SkylineDx Hematological Malignancies Disease Product Offerings

Table 35. SkylineDx Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 36. AgenaBio Corporate Summary

Table 37. AgenaBio Hematological Malignancies Disease Product Offerings

Table 38. AgenaBio Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 39. Signal Genetics Corporate Summary

Table 40. Signal Genetics Hematological Malignancies Disease Product Offerings

Table 41. Signal Genetics Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 42. Pfizer Corporate Summary

Table 43. Pfizer Hematological Malignancies Disease Product Offerings

Table 44. Pfizer Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 45. Roche Corporate Summary



- Table 46. Roche Hematological Malignancies Disease Product Offerings
- Table 47. Roche Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 48. Sanofi-Aventis Corporate Summary
- Table 49. Sanofi-Aventis Hematological Malignancies Disease Product Offerings
- Table 50. Sanofi-Aventis Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 51. Cancer Genetics Inc Corporate Summary
- Table 52. Cancer Genetics Inc Hematological Malignancies Disease Product Offerings
- Table 53. Cancer Genetics Inc Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 54. Illumina Corporate Summary
- Table 55. Illumina Hematological Malignancies Disease Product Offerings
- Table 56. Illumina Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 57. NeoGenomics Corporate Summary
- Table 58. NeoGenomics Hematological Malignancies Disease Product Offerings
- Table 59. NeoGenomics Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 60. Exiqon Corporate Summary
- Table 61. Exiqon Hematological Malignancies Disease Product Offerings
- Table 62. Exiqon Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 63. Regulus Therapeutics Corporate Summary
- Table 64. Regulus Therapeutics Hematological Malignancies Disease Product Offerings
- Table 65. Regulus Therapeutics Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 66. Rosetta Genomics Corporate Summary
- Table 67. Rosetta Genomics Hematological Malignancies Disease Product Offerings
- Table 68. Rosetta Genomics Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 69. Sequentia Corporate Summary
- Table 70. Sequentia Hematological Malignancies Disease Product Offerings
- Table 71. Sequentia Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)
- Table 72. Takeda Pharma Corporate Summary
- Table 73. Takeda Pharma Hematological Malignancies Disease Product Offerings
- Table 74. Takeda Pharma Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)



Table 75. Celgene Corporate Summary

Table 76. Celgene Hematological Malignancies Disease Product Offerings

Table 77. Celgene Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 78. Amgen Corporate Summary

Table 79. Amgen Hematological Malignancies Disease Product Offerings

Table 80. Amgen Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 81. Ono Pharma Corporate Summary

Table 82. Ono Pharma Hematological Malignancies Disease Product Offerings

Table 83. Ono Pharma Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 84. Abbott Corporate Summary

Table 85. Abbott Hematological Malignancies Disease Product Offerings

Table 86. Abbott Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 87. BMS Corporate Summary

Table 88. BMS Hematological Malignancies Disease Product Offerings

Table 89. BMS Hematological Malignancies Disease Revenue (US\$, Mn), (2017-2022)

Table 90. Mundipharma Corporate Summary

Table 91. Mundipharma Hematological Malignancies Disease Product Offerings

Table 92. Mundipharma Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 93. Novartis Corporate Summary

Table 94. Novartis Hematological Malignancies Disease Product Offerings

Table 95. Novartis Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

Table 96. MorphoSys Corporate Summary

Table 97. MorphoSys Hematological Malignancies Disease Product Offerings

Table 98. MorphoSys Hematological Malignancies Disease Revenue (US\$, Mn),  
(2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Hematological Malignancies Disease Segment by Type in 2021
- Figure 2. Hematological Malignancies Disease Segment by Application in 2021
- Figure 3. Global Hematological Malignancies Disease Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Hematological Malignancies Disease Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Hematological Malignancies Disease Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2021
- Figure 8. By Type - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Hematological Malignancies Disease Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Hematological Malignancies Disease Revenue Market Share, 2017-2028
- Figure 12. US Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Hematological Malignancies Disease Revenue Market Share, 2017-2028
- Figure 16. Germany Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Hematological Malignancies Disease Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Hematological Malignancies Disease Revenue Market Share, 2017-2028

Figure 24. China Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hematological Malignancies Disease Revenue Market Share, 2017-2028

Figure 30. Brazil Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hematological Malignancies Disease Revenue Market Share, 2017-2028

Figure 33. Turkey Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hematological Malignancies Disease Revenue, (US\$, Mn), 2017-2028

Figure 37. Affymetrix Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. SkylineDx Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. AgenaBio Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Signal Genetics Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Pfizer Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Roche Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Sanofi-Aventis Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Cancer Genetics Inc Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Illumina Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. NeoGenomics Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Exiqon Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Regulus Therapeutics Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Rosetta Genomics Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Sequentia Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Takeda Pharma Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Celgene Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Amgen Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Ono Pharma Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Abbott Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. BMS Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. Mundipharma Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 58. Novartis Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 59. MorphoSys Hematological Malignancies Disease Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Hematological Malignancies Disease Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/HF272CB0F3A6EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF272CB0F3A6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970